Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study

Dermatology. 2015;230(4):308-13. doi: 10.1159/000371416. Epub 2015 Mar 4.


Background: Alopecia areata (AA) is an immune-mediated disease that targets anagen hair follicles. Despite various therapeutic options, there is no cure for AA. Prostaglandin analogues have been recognized as being capable of inducing hypertrichosis.

Objective: To compare the efficacy and safety of bimatoprost to those of corticosteroid in the treatment of scalp AA.

Methods: Thirty adult patients with patchy AA (S1) were included. Two AA patches were randomly assigned to treatment either by mometasone furoate 0.1% cream once daily (area A) or bimatoprost 0.03% solution twice daily (area B) for 3 months. Patients were assessed using the Severity of Alopecia Tool (SALT) scoring system for hair re-growth.

Results: All responding AA patches showed significant reduction in their SALT score after therapy. Area B demonstrated significantly better results regarding rapidity of response in weeks, percentage of hair re-growth and side effects compared to area A.

Conclusion: Bimatoprost solution represents a therapeutic option for scalp AA.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Alopecia Areata / drug therapy*
  • Bimatoprost / adverse effects
  • Bimatoprost / therapeutic use*
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / therapeutic use*
  • Female
  • Hair / growth & development
  • Humans
  • Male
  • Middle Aged
  • Mometasone Furoate / adverse effects
  • Mometasone Furoate / therapeutic use*
  • Pilot Projects
  • Prospective Studies
  • Scalp
  • Severity of Illness Index
  • Single-Blind Method
  • Skin Cream / therapeutic use
  • Young Adult


  • Dermatologic Agents
  • Mometasone Furoate
  • Bimatoprost